Inflammatory Indexes as Prognostic Factors of Survival in Geriatric Patients with Hepatocellular Carcinoma: A Case Control Study of Eight Slovak Centers.
geriatric patients
hepatocellular cancer
overall survival
progression-free survival
Journal
Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588
Informations de publication
Date de publication:
19 Jul 2022
19 Jul 2022
Historique:
received:
03
06
2022
revised:
08
07
2022
accepted:
14
07
2022
entrez:
27
7
2022
pubmed:
28
7
2022
medline:
28
7
2022
Statut:
epublish
Résumé
Background and Aims: Hepatocellular cancer (HCC) often occurs in geriatric patients. The aim of our study was to compare overall survival and progression-free survival between geriatric patients (>75 years) and patients younger than 75 years and to identify predictive factors of survival in geriatric patients with HCC. Material and Methods: We performed a retrospective analysis of patients with HCC diagnosed in Slovakia between 2010−2016. Cases (HCC patients ≥75 years) were matched to controls (HCC patients <74 years) based on the propensity score (gender, BCLC stage and the first-line treatment). Results: We included 148 patients (84 men, 57%) with HCC. There were no differences between cases and controls in the baseline characteristics. The overall survival in geriatric patients with HCC was comparable to younger controls (p = 0.42). The one-, two-, and three-year overall survival was 42% and 31%, 19% and 12%, and 12% and 9% in geriatric patients and controls, respectively (p = 0.2, 0.4, 0.8). Similarly, there was no difference in the one- and two-year progression-free survival: 28% and 18% vs. 10% and 7% in geriatric HCC patients and controls, respectively (p = 0.2, 1, -). There was no case−control difference between geriatric HCC patients and younger HCC controls in the overall survival in the subpopulation of patients with no known comorbidities (p = 0.5), one and two comorbidities (p = 0.49), and three or more comorbidities (p = 0.39). Log (CRP), log (NLR), log (PLR), and log (SII) were all associated with the three-year survival in geriatric HCC patients in simple logistic regression analyses. However, this time, only log (NLR) remained associated even after controlling for the age and BCLC confounding (OR 5.32, 95% CI 1.43−28.85). Conclusions. We found no differences in overall survival and progression-free survival between older and younger HCC patients. Parameters of subclinical inflammation predict prognosis in geriatric patients with HCC. A limitation of the study is small number of the treated patients; therefore, further investigation is warranted.
Identifiants
pubmed: 35887947
pii: jcm11144183
doi: 10.3390/jcm11144183
pmc: PMC9318669
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
World J Gastroenterol. 2013 Apr 28;19(16):2521-8
pubmed: 23674854
Gut. 2010 Mar;59(3):387-96
pubmed: 20207642
World J Gastroenterol. 2013 Dec 14;19(46):8459-67
pubmed: 24379563
Cytokine Growth Factor Rev. 2007 Feb-Apr;18(1-2):171-82
pubmed: 17329145
Clin Cancer Res. 2014 Dec 1;20(23):6212-22
pubmed: 25271081
Updates Surg. 2021 Aug;73(4):1371-1380
pubmed: 33687694
Hepatology. 2000 Apr;31(4):864-71
pubmed: 10733541
Hepatol Res. 2010 Oct;40(10):997-1005
pubmed: 20887335
Cancers (Basel). 2021 Apr 01;13(7):
pubmed: 33915755
J Cancer. 2014 Jul 17;5(7):590-7
pubmed: 25057310
PLoS One. 2020 Mar 26;15(3):e0230879
pubmed: 32214401
J Gastrointest Surg. 2021 May;25(5):1124-1133
pubmed: 32607856
Liver Int. 2014 Aug;34(7):1109-17
pubmed: 24512125
Liver Int. 2020 Aug;40(8):2008-2020
pubmed: 32279446
Br J Cancer. 2021 Jan;124(2):407-413
pubmed: 33071284
Surg Endosc. 2020 Feb;34(2):658-666
pubmed: 31093748
Ann Oncol. 2018 Oct 1;29(Suppl 4):iv238-iv255
pubmed: 30285213
Hepatology. 2018 Aug;68(2):723-750
pubmed: 29624699
Transl Lung Cancer Res. 2019 Dec;8(6):886-894
pubmed: 32010567
Hepatology. 2015 Jul;62(1):279-91
pubmed: 25810240
Int J Hyperthermia. 2014 Nov;30(7):471-9
pubmed: 25314335
Adv Cancer Res. 2007;97:247-74
pubmed: 17419949
J Cancer Res Ther. 2018 Jan;14(1):84-89
pubmed: 29516965
World Neurosurg. 2019 Jul;127:e261-e267
pubmed: 30898756
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Tumour Biol. 2015 Apr;36(4):2263-9
pubmed: 25409616
Nat Immunol. 2018 Mar;19(3):222-232
pubmed: 29379119
PeerJ. 2019 Oct 14;7:e7132
pubmed: 31632844
Ann Surg Oncol. 2007 Apr;14(4):1449-57
pubmed: 17235712
J Clin Oncol. 2015 Feb 20;33(6):550-8
pubmed: 25512453
Bratisl Lek Listy. 2001;102(1):5-14
pubmed: 11723675
Oncologist. 2011;16(12):1721-8
pubmed: 22135121
Eur J Gastroenterol Hepatol. 2017 Jan;29(1):48-55
pubmed: 27623000
J Gastrointest Oncol. 2021 Apr;12(2):735-750
pubmed: 34012662
Hepatol Res. 2020 Jan;50(1):75-83
pubmed: 31660700
Am J Surg. 2019 May;217(5):899-905
pubmed: 30819401
Dig Surg. 2020;37(6):447-455
pubmed: 32690855
Ann Oncol. 2005 May;16(5):767-72
pubmed: 15817594
Front Oncol. 2022 Jan 19;11:791912
pubmed: 35127498
J Gastroenterol Hepatol. 2010 Feb;25(2):403-7
pubmed: 19929922
J Hepatol. 2018 Jul;69(1):182-236
pubmed: 29628281
J Cancer. 2013 Sep 14;4(8):635-43
pubmed: 24155775
J Cancer. 2014 Jun 07;5(7):499-509
pubmed: 24963354
Cancer Manag Res. 2021 Apr 13;13:3209-3218
pubmed: 33880063
Cancer Chemother Pharmacol. 2009 Mar;63(4):571-82
pubmed: 19083000
JAMA. 2004 Jun 9;291(22):2720-6
pubmed: 15187053
Onco Targets Ther. 2019 Sep 02;12:7129-7137
pubmed: 31564897
Gastroenterology. 2007 Jun;132(7):2557-76
pubmed: 17570226
J Clin Oncol. 2020 Dec 20;38(36):4317-4345
pubmed: 33197225
J Hepatol. 2015 Dec;63(6):1390-6
pubmed: 26256438
World J Surg. 2018 Aug;42(8):2542-2550
pubmed: 29464343
Oncologist. 2011;16(3):310-8
pubmed: 21349948
Eur J Gastroenterol Hepatol. 2013 Aug;25(8):912-9
pubmed: 23470356
J Hepatol. 2013 Oct;59(4):753-61
pubmed: 23707371
Int Immunopharmacol. 2020 Nov;88:106939
pubmed: 33182039
Med Oncol. 2013 Mar;30(1):446
pubmed: 23307255